The frequency of reproducibility issues – daily and weekly for some respondents – was alarming. In terms of reproducibility, there are evidently more challenges facing analytical labs than I initially suspected – and the issues don’t appear to stem from one particular tool or application. What stands out most for me is the section on reproducibility and validation (see Figure 1). Which survey result is most prominent in your mind? Indeed, we also sought out an independent partner with a global reach – The Analytical Scientist – to help conduct the survey, analyze the data, and prepare the report. And though we are clearly interested in the results of the survey, our intent from the start was to create something that would have value for the industry as a whole – very much in line with the aforementioned trends of partnerships and collaboration. With so many trends and challenges pushing and pulling, it felt like a great time to grab our survey camera to take a snapshot of the industry as viewed by those in pharmaceutical analysis and QC. Layered on top of those major trends in 20 is the COVID-19 pandemic, which has had its own influence in shaping current trends and driving new ones. We were already well aware that the pharma value chain has been rapidly evolving over the last 5-10 years – driven by several key trends: i) the emergence of biologics from a niche position to a more mainstream market, ii) the rise of partnerships and collaboration, which essentially represents a shift in the pharma development mindset, and iii) an increasingly diverse spectrum of organizations –from the large multinational “big pharma” companies we know and love (!) to tiny biotech start ups with a single investigational new drug (IND). What were the motivations behind the survey?
0 kommentar(er)
